United Therapeutics Corporation Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
United Therapeutics Corporation (UTHR) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $26.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-25
- United Therapeutics Corporation effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $26.60M, a 2.21% decline from fiscal 2024.
- United Therapeutics Corporation effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $27.20M, a 43.16% increase from fiscal 2023.
- United Therapeutics Corporation effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $19.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $26.60M 10-K · filed 2026-02-25 |
| 2024-12-31 | $27.20M 10-K · filed 2026-02-25 |
| 2023-12-31 | $19.00M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |